No Picture
News

Data from NantHealth’s GPS Cancer platform reveals increased opportunities for HER2 directed therapy in colorectal cancer patients

SAN FRANCISCO–(BUSINESS WIRE)–NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced Results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer (CRC) patie… […]

No Picture
News

Horizon Therapeutics plc Announces Changes in Research and Development Organization

DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) today announced changes to its research and development organization structure. Effective immediately, Elizabeth H.Z. Thompson, Ph.D., group vice president, clinical development and exter… […]

No Picture
News

Sun BioPharma, Inc. Summarizes SBP-101 Phase 1 Clinical Data Presented at ASCO 2020 Annual Gastrointestinal Cancers Symposium

SAN FRANCISCO, Jan. 24, 2020 (GLOBE NEWSWIRE) — Sun BioPharma, Inc. (OTCQB: SNBP), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of people with pancreatic cancer, today summarized initial Phase 1  cl… […]

No Picture
News

Gilead dusts off a failed Ebola drug as coronavirus spreads; Exelixis boasts positive Ph I/II data

→ Less than a year ago Gilead‘s antiviral remdesivir failed to make the cut as investigators considered a raft of potential drugs that could be used against an Ebola outbreak. But it may gain a new mission with the outbreak of the coronavirus in China,… […]

No Picture
News

Diabetes-focused Poxel names Eli Lilly vet David Moller as CSO; Acceleron’s CBO hops ship to lead startup

David Moller
→ After passing their third straight Phase III trial for its new kind of diabetes tablet in Japan, French pharma Poxel has tapped David Moller as CSO. Moller has focused his career in the fields of diabetes and metabolic disorders. He most… […]

No Picture
News

Genentech Provides an Update on Phase III Study of Tecentriq in People With Muscle-invasive Urothelial Cancer

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy treat… […]